Real-world safety and effectiveness of lurasidone in Chinese children and adolescents with schizophrenia: Findings from a prospective cohort

Table 2 Analysis of covariance-adjusted changes in Brief Psychiatric Rating Scale and International Classification of Diseases (11th Revision) symptom rating scores in pediatric and adult patients receiving lurasidone monotherapy through surveillance, mean ± SD/n (%)

Outcome measures	Pediatric (n = 140)	Adult (n = 1332)	Adjusted P value
BPRS
Total score-baseline	45.6 ± 15.67	43.9 ± 16.50
Reduction in total score-2/4 weeks	9 ± 8.73	9.2 ± 9.87
Reduction in total score-6/8 weeks	14.9 ± 12.28	14.5 ± 12.46
Reduction in total score-12 weeks	19.6 ± 13.72	17.3 ± 14.39
Reduction in total score-12 weeks ≥ 50%	52 (37.1)	370 (27.8)
Anxiety-depression-baseline	10.8 ± 4.15	9.6 ± 4.30	0.020
Reduction in anxiety-depression-12 weeks	4.6 ± 3.47	3.5 ± 3.33
ICD-11 symptom rating scale
Reduction in positive symptoms-12 weeks	1.5 ± 1.34	0.8 ± 1.17
Reduction in negative symptoms-12 weeks	0.6 ± 0.88	0.4 ± 0.82
Reduction in depressive mood symptoms-12 weeks	0.8 ± 1.06	0.4 ± 0.79	0.013
Reduction in manic mood symptoms-12 weeks	0.2 ± 0.45	0.2 ± 0.63	0.018
Reduction in psychomotor symptoms-12 weeks	0.3 ± 0.84	0.3 ± 0.76	< 0.001
Reduction in cognitive symptoms-12 weeks	0.8 ± 0.95	0.4 ± 0.85	0.036
Adherence
Patients completed 12 weeks-surveillance	135 (96.4)	1228 (92.2)	0.029

BPRS: Brief Psychiatric Rating Scale; ICD-11: International Classification of Diseases 11th Revision.